Pharmaceutical composition for preventing or treating cancer, comprising BTK degrader and bcl-6 degrader

The combination of BTK and Bcl-6 degraders using PROTAC technology in a pharmaceutical composition effectively addresses the limitations of current cancer therapies by synergistically inhibiting cancer cell growth, particularly in cancers resistant to conventional treatments.

WO2024228505A1PCT designated stage expired Publication Date: 2024-11-07INJE UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/005405
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-03
Filing Date
2024-04-22
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current PROTAC-based tumor protein degradation therapies for cancer exhibit variable efficacy and are often hindered by resistance in cancer cells, necessitating the development of combination therapies that can effectively target multiple proteins to enhance treatment outcomes.

Method used

A pharmaceutical composition comprising a BTK degrader and a Bcl-6 degrader, both based on PROTAC technology, is administered in combination to selectively degrade the BTK and Bcl-6 proteins, leveraging their synergistic effects to inhibit cancer cell growth across various types, including lymphoma, leukemia, and lung cancer.

Benefits of technology

The combined treatment demonstrates superior cancer cell growth inhibition compared to single-agent treatments, offering a therapeutic approach that can target cancer resistant to conventional drugs, thereby enhancing treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024005405_07112024_PF_FP_ABST
    Figure KR2024005405_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a BTK-degrader and a Bcl-6-degrader. The pharmaceutical composition of the present invention selectively degrades a target protein through the Proteolysis-Targeting Chimera (PROTAC) technology-based BTK-degrader and the Bcl-6-degrader of the present invention, and thus has an effect of preventing or treating cancer and can create a therapeutic effect against cancer having resistance to conventional drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition for preventing or treating cancer comprising a BTK degrader and a BCL-6 degrader

[0001] This patent application claims priority to Republic of Korea Patent Application No. 10-2023-0057801, filed with the Korean Intellectual Property Office on May 3, 2023, the disclosure of which is incorporated herein by reference.

[0002] This invention was made under the support of the Ministry of Science and ICT under the project identification number 1711182663 and project number 2022R1F1A1061005. The research management specialized institution of the said project is the National Research Foundation of Korea, the research project name is "Individual Basic Research (Ministry of Science and ICT)", the research project name is "Development of a combination immunotherapy using a PROTAC-based epigenetic regulator EZH2 target drug and an immune checkpoint inhibitor for the treatment of refractory lymphoma", the main institution is Inje University, and the research period is from 2022.06.01 to 2025.02.28.

[0003] The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a BTK degrader and a Bcl-6 degrader. Specifically, the BTK degrader and Bcl-6 degrader of the present invention can selectively degrade a target protein based on proteolysis-targeting chimera (PROTAC) technology, and thus, the pharmaceutical composition of the present invention can produce a preventive or therapeutic effect on blood cancers such as lymphoma and leukemia, colon cancer, or lung cancer.

[0004] Blood cancer is a disease that occurs when blood cells that make up the blood change into cancer cells and cause abnormalities in the hematopoietic or lymphatic organs. Leukemia, which is caused by cancer cells developing in the hematopoietic cells that make blood and preventing the production of normal blood cells, is accompanied by symptoms such as infection, anemia, and bleeding; lymphoma, which is caused by the change of lymphocytes, which are responsible for the body's immune system, into cancer cells and is accompanied by symptoms such as infection and bleeding; and multiple myeloma, which is caused by the change of plasma cells that produce antibodies into cancer cells and is accompanied by symptoms such as various bone diseases and infections.

[0005] Combination therapy of chemotherapy and hematopoietic stem cell transplantation is primarily used to treat blood cancer. Additionally, radiotherapy and symptomatic treatment to alleviate pain or bone pathology caused by blood cancer are also utilized. Conventional cytotoxic chemotherapy drugs, such as melphalan, doxorubicin, and etoposide, used to treat blood cancer, have fatal effects on both cancer cells and normal cells, causing numerous side effects. Furthermore, they are associated with a high incidence of drug-resistant cancer cells and relapse after treatment. Therefore, research and development are continuously underway on targeted therapies using antibody-based anticancer drugs and small molecule inhibitors to replace conventional chemotherapy drugs.

[0006] Meanwhile, PROteolysis Targeting Chimera (PROTAC) technology, which utilizes the ubiquitin-proteasome system (UPS) as a targeted treatment technology for cancer cells, has been proposed and research is ongoing to selectively degrade target proteins. PROTAC induces ubiquitination of the target protein by bringing it into proximity with the E3 ubiquitin ligase, resulting in natural target protein degradation by the patient's body's protein degradation system. It is a technology with high potential as a treatment for various diseases, including blood cancer.

[0007] However, there are reports that PROTAC-based tumor protein degradation does not result in an effective level of tumor growth inhibition, or that the target protein degradation effect of PROTAC varies greatly depending on the tissue of administration. Therefore, there is a need to develop a PROTAC-based anticancer therapy that can exhibit an anticancer effect greater than that of conventional chemical drugs.

[0008] Accordingly, the inventors of the present invention confirmed that by co-administering BTK protein and Bcl-6 protein targeting agents based on PROTAC technology, an excellent therapeutic effect can be created for cancers resistant to conventional drugs.

[0009] Accordingly, the purpose of the present invention is to provide a pharmaceutical composition for preventing or treating cancer, which comprises a BTK decomposer and a Bcl-6 decomposer as active ingredients.

[0010] Another object of the present invention is to provide a method for preventing or treating cancer using a pharmaceutical composition comprising a BTK decomposer and a Bcl-6 decomposer as active ingredients.

[0011] Another object of the present invention is to provide a use for the prevention or treatment of cancer by combined administration of a BTK degrader and a Bcl-6 degrader.

[0012] The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a BTK decomposer and a Bcl-6 decomposer, and the pharmaceutical composition of the present invention can effectively prevent or treat blood cancers such as lymphoma and leukemia, colon cancer, or lung cancer.

[0013] Hereinafter, the present invention will be described in more detail.

[0014] One aspect of the present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a BTK decomposer and a Bcl-6 decomposer as active ingredients.

[0015] The term "BTK (Bruton's tyrosine kinase) protein" in this specification refers to a protein that is key to B cell development by allowing a series of signal transduction processes to be performed on B cells through phosphorylation of the B cell receptor, which is a tyrosine kinase encoded by the BTK gene. If a mutation occurs in the BTK gene encoding the BTK protein, the maturation, migration, or apoptosis processes of B cells may not be controlled, which may cause diseases such as leukemia, lymphoma, and multiple sclerosis. Therefore, drugs such as ibrutinib and acalabrutinib have been developed to treat BTK-related diseases by degrading the BTK protein or inhibiting the expression of the BTK gene, and research and development of drugs targeting the BTK protein or gene are continuously being conducted.

[0016] The term “BTK degrader” as used herein means an agent that targets and degrades the BTK protein.

[0017] The term "Bcl-6 (B-cell lymphoma 6) protein" in this specification refers to a zinc finger motif-based transcription factor encoded by the BCL-6 gene, which is a key protein in the differentiation and proliferation of helper T cells into follicular helper T cells. When the BCL-6 gene encoding the Bcl-6 protein is translocated or hypermutated within a chromosome, or when a mutation occurs in a transcription factor involved in BCL-6 gene expression, resulting in an abnormality in BCL-6 gene expression, malignant lymphomas such as B-cell lymphoma, Burkitt's lymphoma, and follicular lymphoma may be induced. Therefore, the detection and analysis results for the Bcl-6 protein or BCL-6 gene can be utilized for the diagnosis of lymphoma, and a therapeutic effect for malignant lymphoma can be created through the removal / decomposition of the Bcl-6 protein or the removal / inhibition of the BCL-6 gene in cancer cells.

[0018] The term “Bcl-6 degrader” as used herein means an agent that targets and degrades the Bcl-6 protein.

[0019] The term "comprising as an active ingredient" in this specification means including an amount sufficient to achieve a specific effect of a BTK degrader or Bcl-6 degrader, for example, activity for preventing or treating cancer.

[0020] The term “prevention” in this specification means any action that inhibits or delays the progression of cancer by administering the pharmaceutical composition of the present invention.

[0021] The term “treatment” as used herein means inhibition of cancer development, alleviation of cancer, and elimination of cancer.

[0022] In one embodiment of the present invention, the BTK degrader and Bcl-6 degrader are characterized in that they are PROTAC (Proteolysis targeting chimera) based.

[0023] In the present invention, a PROTAC molecule is a heterobifunctional compound comprising a ubiquitin ligase binding ligand, a target protein binding ligand, and a linker connecting them, which can bring a target protein into the vicinity of an E3 ligase, resulting in the degradation of the target protein. In one embodiment of the present invention, the BTK degrader and / or Bcl-6 degrader is a PROTAC molecule.

[0024] In one embodiment of the present invention, the PROTAC-based BTK degrader is an agent that brings the BTK protein into the vicinity of the E3 ligase, thereby degrading the BTK protein.

[0025] In one embodiment of the present invention, a PROTAC-based Bcl-6 degrader is an agent that brings Bcl-6 protein into the vicinity of an E3 ligase, thereby degrading Bcl-6 protein.

[0026] In one embodiment of the present invention, the BTK decomposer may be, but is not limited to, MT-802.

[0027] In one embodiment of the present invention, the MT-802 is a compound having a structure represented by the following structural formula 1.

[0028] [Structural formula 1]

[0029]

[0030] In one embodiment of the present invention, the Bcl-6 degrader may be, but is not limited to, BI-3802.

[0031] In one embodiment of the present invention, the BI-3802 is a compound having a structure of structural formula 2 below.

[0032] [Structural formula 2]

[0033]

[0034] The present inventors confirmed that when the BTK decomposition agent and Bcl-6 decomposition agent were treated alone, the minimum molar concentration at which both drugs were deemed effective was 5 μM. Accordingly, when the BTK decomposition agent and Bcl-6 decomposition agent were used in combination, these results were reflected. When each drug was included in a pharmaceutical composition at a molar ratio of 1:1, the minimum molar concentration at which they were effective, 5 μM, was included. As a result, it was confirmed that the combination treatment had a superior cancer cell growth inhibition effect compared to the single treatment.

[0035] In one embodiment of the present invention, the molar ratio of the BTK degrader and the Bcl-6 degrader is 1:10 to 10:1, for example, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 2:9, 2:7, 2:5, 2:3, 3:8, 3:7, 3:5, 3:4, 4:9, 4:7, 4:5, 5:9, 5:8, 5:7, 5:6, 6:7, 7:8, 7:9, 7:10, 8:9, 9:10, 10:9, 10:7, 10:3, 10:1, 9:8, 9:7, 9:5, 9:4, 9:2, It can be 9:1, 8:7, 8:5, 8:3, 8:1, 7:6, 7:5, 7:4, 7:3, 7:2, 7:1, 6:5, 6:1, 5:4, 5:3, 5:2, 5:1, 4:3, 4:1, 3:2, 3:1, 2:1 or 1:1, for example, but not limited to, 1:3 to 3:1.

[0036] In one embodiment of the present invention, the pharmaceutical composition comprises a BTK degrader at a concentration of 1 to 20 μM and a Bcl-6 degrader at a concentration of 1 to 20 μM.

[0037] In one embodiment of the present invention, the pharmaceutical composition comprises a BTK degrading agent at a concentration of 1 to 20 μM, 1 to 15 μM, 1 to 10 μM, 2 to 20 μM, 2 to 15 μM, 2 to 10 μM, 3 to 20 μM, 3 to 15 μM, 3 to 10 μM, 4 to 20 μM, 4 to 15 μM, 4 to 10 μM, 4 to 8 μM, 4 to 6 μM, 5 to 20 μM, 5 to 15 μM, or 5 to 10 μM, for example, at a concentration of 5 μM.

[0038] The Bcl-6 degrader may be present at a concentration of 1 to 20 μM, 1 to 15 μM, 1 to 10 μM, 2 to 20 μM, 2 to 15 μM, 2 to 10 μM, 3 to 20 μM, 3 to 15 μM, 3 to 10 μM, 4 to 20 μM, 4 to 15 μM, 4 to 10 μM, 4 to 8 μM, 4 to 6 μM, 5 to 20 μM, 5 to 15 μM, or 5 to 10 μM, for example, at a concentration of 5 μM.

[0039] In one embodiment of the present invention, the cancer may be at least one selected from the group consisting of leukemia, lymphoma, multiple myeloma, colorectal cancer, and lung cancer.

[0040] In one embodiment of the present invention, the leukemia is acute lymphoblastic leukemia, B cell precursor acute lymphoblastic leukemia, T cell precursor acute lymphoblastic leukemia, acute biphenotypic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, B cell prolymphocytic leukemia, acute myelogenous leukemia, acute promyelocytic leukemia, acute myeloblastic leukemia, acute megakaryoblastic leukemia, chronic myelogenous leukemia It may be chronic myelomonocytic leukemia, hairy cell leukemia, T cell prolymphocytic leukemia, large granular lymphocytic leukemia, adult T cell leukemia, or chronic eosinophilic leukemia.

[0041] In one embodiment of the present invention, the lymphoma is Hodgkin lymphoma, nodular lymphocyte predominant Hodgkin lymphoma, lymphocyte rich classical Hodgkin lymphoma, nodular sclerosis classical Hodgkin lymphoma, mixed cellularity classical Hodgkin lymphoma, lymphocyte depletion classical Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, B-cell non-Hodgkin lymphoma, Burkitt lymphoma, large B cell lymphoma, diffuse large B cell lymphoma, primary effusion lymphoma It may be primary effusion lymphoma, plasmablastic lymphoma, extranodal NK / T cell lymphoma, peripheral T cell lymphoma, angioimmunoblastic T cell lymphoma, or follicular lymphoma.

[0042] In one embodiment of the present invention, the multiple myeloma may be light chain myeloma, non-secretory myeloma, solitary plasmacytoma, extramedullary plasmacytoma, monoclonal gammopathy, smoldering multiple myeloma, immunoglobulin D myeloma (IgD myeloma), immunoglobulin A myeloma (IgA myeloma), immunoglobulin E myeloma (IgE myeloma), or immunoglobulin G myeloma (IgG myeloma).

[0043] In one embodiment of the present invention, the colon cancer may be adenocarcinoma, gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, or lymphoma.

[0044] In one embodiment of the present invention, the lung cancer may be non-small cell lung cancer, small cell lung cancer, pancoast tumor, or lung carcinoid tumors.

[0045] In one embodiment of the present invention, the non-small cell lung cancer may be squamous cell carcinoma, adenocarcinoma, or large-cell carcinoma.

[0046] The pharmaceutical composition of the present invention may additionally comprise a pharmaceutically acceptable carrier.

[0047] The term "pharmaceutically acceptable" as used herein means, as commonly used in the pharmaceutical field, that when administered, it does not stimulate the organism and does not inhibit the biological activity and properties of the administered compound.

[0048] In the present invention, any carrier commonly used in the art may be used as the carrier. Non-limiting examples of the carrier include saline solution, sterile water, Ringer's solution, buffered saline, albumin injection solution, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, maltodextrin, glycerol, ethanol, or combinations thereof.

[0049] The pharmaceutical composition of the present invention may be used by adding other pharmaceutically acceptable additives, such as excipients, diluents, antioxidants, buffers, or bacteriostatic agents, if necessary, and may be used by additionally adding fillers, bulking agents, wetting agents, disintegrating agents, dispersing agents, surfactants, binders, or lubricants.

[0050] The pharmaceutical composition of the present invention may be administered in various dosages depending on factors such as the formulation method, administration method, patient age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity. The dosage may be determined or prescribed as an effective dosage for the desired treatment or prevention. For example, the daily dosage of the pharmaceutical composition of the present invention may be 0.0001-1000 mg / kg.

[0051] The pharmaceutical composition of the present invention can be manufactured in a unit dose form or can be manufactured by placing it in a multi-dose container by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily performed by a person having ordinary skill in the art to which the present invention pertains, and thereby. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of an extract, powder, suppository, powder, granule, tablet or capsule, and may additionally include a dispersant or stabilizer, but is not limited thereto.

[0052] The dosage of the pharmaceutical composition of the present invention may vary depending on the patient's age, weight, sex, dosage form, health condition, and disease severity, and may be administered once or several times a day at regular intervals, depending on the judgment of a doctor or pharmacist. For example, the daily dosage may be 1 to 1000 ug / mL based on the active ingredient content, but this is an example of an average case, and the dosage may be higher or lower depending on individual differences.

[0053] Another aspect of the present invention relates to a method for preventing or treating cancer by administering to a subject a pharmaceutical composition comprising a BTK decomposer and a Bcl-6 decomposer as active ingredients.

[0054] In one embodiment of the present invention, the BTK degrader and the Bcl-6 degrader may be administered simultaneously, sequentially, or alternatingly. When the BTK degrader and the Bcl-6 degrader are administered alternately, each agent may be sequentially administered at a time interval of, but not limited to, about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 30 minutes, about 45 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 12 hours, about 24 hours, about 48 hours, about 72 hours, about 96 hours, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 8 weeks, or about 12 weeks.

[0055] In one embodiment of the present invention, the BTK degrading agent may be administered at a dose of, but is not limited to, 0.1 mg / kg to 1000 mg / kg, 0.1 mg / kg to 500 mg / kg, 0.1 mg / kg to 100 mg / kg, 0.1 mg / kg to 50 mg / kg, 1 mg / kg to 1000 mg / kg, 1 mg / kg to 500 mg / kg, 1 mg / kg to 100 mg / kg, 1 mg / kg to 50 mg / kg, 5 mg / kg to 1000 mg / kg, 5 mg / kg to 500 mg / kg, 5 mg / kg to 100 mg / kg, or 5 mg / kg to 50 mg / kg.

[0056] In one embodiment of the present invention, the Bcl-6 degrader may be administered at a dose of, but is not limited to, 0.1 mg / kg to 1000 mg / kg, 0.1 mg / kg to 500 mg / kg, 0.1 mg / kg to 100 mg / kg, 0.1 mg / kg to 50 mg / kg, 1 mg / kg to 1000 mg / kg, 1 mg / kg to 500 mg / kg, 1 mg / kg to 100 mg / kg, 1 mg / kg to 50 mg / kg, 5 mg / kg to 1000 mg / kg, 5 mg / kg to 500 mg / kg, 5 mg / kg to 100 mg / kg, or 5 mg / kg to 50 mg / kg.

[0057] In one embodiment of the present invention, the pharmaceutical composition may be administered 1 to 6 times, 1 to 5 times, 1 to 4 times, or 1 to 3 times daily, as needed, but is not limited thereto.

[0058] In one embodiment of the present invention, the pharmaceutical composition may be in the form of, but is not limited to, tablets, capsules, granules, syrups, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, creams, and injections.

[0059] The term "subject" in this specification may be a mammal including a human, for example, but not limited to, a human, monkey, cow, horse, sheep, pig, cat, dog, mouse, rat, rabbit or guinea pig.

[0060] The term "administration" as used herein means providing a given substance to a subject by any suitable method, and the route of administration of the composition comprising the BTK decomposer and Bcl-6 decomposer of the present invention as active ingredients may be administered orally or parenterally through any common route as long as it can reach the target tissue. In addition, the composition of the present invention may be administered using any device capable of delivering the active ingredient to the target cell. For example, the pharmaceutical composition of the present invention may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, topical administration, intranasal administration, intrapulmonary administration, rectal administration, intrathecal administration, ocular administration, skin administration, and transdermal administration, but is not limited thereto.

[0061] Another aspect of the present invention relates to a use of a pharmaceutical composition comprising a BTK decomposer and a Bcl-6 decomposer as active ingredients for the prevention or treatment of cancer.

[0062] Another aspect of the present invention relates to a method for preventing or treating cancer, comprising administering to a subject in need of treatment an effective amount of a BTK degrader and a Bcl-6 degrader.

[0063] The term “subject” in this specification is meant to include humans (e.g., patients) and mammals (e.g., mice, rats, dogs, cats, rabbits, chickens, monkeys, etc.).

[0064] The term "effective amount" as used herein means an amount (e.g., dose) of a pharmaceutical composition that provides a significant reduction in the clinical symptoms of a disease or condition to be treated without causing excessive toxic side effects.

[0065] The term “dose” as used herein means the weight (e.g., milligrams (mg)) of active substance per kilogram (kg) of body weight of the subject.

[0066] In one embodiment of the present invention, the BTK degrader and the Bcl-6 degrader may be present as separate agents, but are not limited thereto.

[0067] In one embodiment of the present invention, the BTK degrader and the Bcl-6 degrader may be administered simultaneously, sequentially, or alternately. In one embodiment of the present invention, the BTK degrader and the Bcl-6 degrader may be administered in combination.

[0068] The pharmaceutical composition of the present invention not only has a preventive or therapeutic effect on cancer by selectively degrading BTK protein and Bcl-6 protein by including both a BTK degrader and a Bcl-6 degrader, but can also create a preventive or therapeutic effect on cancer that is resistant to conventional drugs.

[0069] Figure 1 is a graph comparing cell survival rates when a BTK decomposition agent (MT-802) and a Bcl-6 decomposition agent (BI-3802) according to one embodiment of the present invention are treated alone or in combination with a lymphoma cell line.

[0070] Figure 2 is a graph comparing cell survival rates when a BTK decomposition agent (MT-802) and a Bcl-6 decomposition agent (BI-3802) according to one embodiment of the present invention are treated alone or in combination with a colon cancer cell line.

[0071] Figure 3 is a graph comparing cell survival rates when a BTK decomposition agent (MT-802) and a Bcl-6 decomposition agent (BI-3802) according to one embodiment of the present invention are treated alone or in combination with a T-cell leukemia cell line.

[0072] Figure 4 is a graph comparing cell survival rates when a BTK decomposition agent (MT-802) and a Bcl-6 decomposition agent (BI-3802) according to one embodiment of the present invention are treated alone or in combination with a lung cancer cell line.

[0073] The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a BTK decomposer and a Bcl-6 decomposer as active ingredients.

[0074] Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these examples are intended only to illustrate the present invention, and the scope of the present invention is not limited by these examples.

[0075] Unless otherwise stated, all numbers, values ​​and / or expressions expressing ingredients, reaction conditions and quantities of ingredients used in this specification are approximations that inherently reflect, among other things, the various uncertainties of measurement that arise in obtaining such values ​​and therefore should be understood as being modified in all instances by the term "about", and when a numerical range is disclosed herein, such range is continuous and includes every value from the minimum value to the maximum value inclusive, unless otherwise stated.

[0076] Also, the term "or" is intended to mean an inclusive "or" rather than an exclusive "or." That is, where the connection or use between constructions is not otherwise specified or clear from the context, i.e., if X includes A; X includes B; or X includes both A and B, "X includes A or B" can be applied to any of these cases.

[0077] And, throughout the specification, whenever a part is said to "include" a component, this does not mean that it excludes other components, but rather that it may include other components, unless otherwise specifically stated.

[0078]

[0079] Example 1: Experimental study of combined treatment of BTK degraders and Bcl-6 degraders on lymphoma cell lines.

[0080] 1-1. Culturing of lymphoma cell lines

[0081] To examine the effect of combined treatment with the BTK decomposition agent and Bcl-6 decomposition agent of the present invention in vitro, lymphoma cell lines were cultured.

[0082] Specifically, Daudi cell line (Korea Cell Line Bank, 10213) infected with Epstein-Barr virus (EBV) among Burkitt's lymphoma cells was used, and 2.0 × 10 cells were cultured per well of a 96-well plate. 4 Cells were seeded at 100 μL. The seeded Daudi cell line was cultured in RPMI medium (Gibco) containing 10% FBS (Gibco), antibiotics (Gibco), and glutamax (Gibco) at 37°C and 5% CO2 in a cell incubator.

[0083]

[0084] 1-2. Combined treatment with BTK degraders and Bcl-6 degraders

[0085] Through Example 1-1, the lymphoma cell line cultured was treated with a BTK decomposition agent alone, a Bcl-6 decomposition agent alone, or a combination of a BTK decomposition agent and a Bcl-6 decomposition agent, and the results were confirmed.

[0086] Specifically, cultured lymphoma cell lines were treated with DMSO to establish a negative control, and 5 μM or 10 μM of the BTK degrader MT-802 (from MedChemExpress ) or Bcl-6 degrader BI-3802 (from MedChemExpress A positive control group was set up by treating the cells alone with 5 μM of the BTK decomposer MT-802 and the Bcl-6 decomposer BI-3802, and an experimental group was set up by treating the cells together with 5 μM of the BTK decomposer MT-802 and the Bcl-6 decomposer BI-3802.

[0087] After an appropriate period of time from treatment with DMSO, BTK, or Bcl-6 degraders for each group, the survival rate of the lymphoma cell lines in each group was determined using the CCK-8 assay, and the results are shown in Fig. 1 and Table 1.

[0088] OD measurement value (450 nm) Normal cell group 0.972 Negative control 1.014 BTK degrader-treated positive control BTK degrader 5 μM 0.390 BTK degrader 10 μM 0.271 Bcl-6 degrader-treated positive control Bcl-6 degrader 5 μM 0.869 Bcl-6 degrader 10 μM 0.487 Experimental group (BTK degrader 5 μM + Bcl-6 degrader 5 μM) 0.220

[0089]

[0090] As a result of the analysis, when lymphoma cell lines were treated with a combination of a BTK degrader (5 μM) and a Bcl-6 degrader (5 μM), the survival rate of the lymphoma cell lines was significantly suppressed compared to when the BTK degrader (5 μM) or Bcl-6 degrader (5 μM) was treated alone, and it was confirmed that the survival rate of the lymphoma cell lines was suppressed statistically significantly more than when the individual degraders were treated in multiple doses (10 μM).

[0091] Specifically, the absorbance of the BTK decomposition agent MT-802 alone treatment group and the Bcl-6 decomposition agent BI-3802 alone treatment group in the lymphoma cell line was 0.271 and 0.487 at 10 μM, respectively, whereas the absorbance of the combined treatment group of the BTK decomposition agent MT-802 (5 μM) and the Bcl-6 decomposition agent BI-3802 (5 μM) was confirmed to be significantly reduced to 0.220.

[0092] That is, it was confirmed that the combined treatment group of MT-802, a BTK inhibitor, and BI-3802, a Bcl-6 inhibitor, had a superior cell growth inhibition effect compared to the single treatment group in the lymphoma cell line. In addition, the average value of the absorbance of the BTK decomposition agent MT-802 10 μM single treatment group and the absorbance of the Bcl-6 decomposition agent BI-3802 10 μM single treatment group was (0.271 + 0.487) / 2 = 0.379, which is lower than the absorbance of the combined treatment group of MT-802 (5 μM), a BTK decomposition agent, and BI-3802 (5 μM), a Bcl-6 decomposition agent, which was 0.220, confirming a synergistic effect.

[0093]

[0094] Example 2: Experimental study of combined treatment with BTK degraders and Bcl-6 degraders on colon cancer cell lines.

[0095] 2-1. Culturing of colon cancer cell lines

[0096] Colon cancer cell line (HCT-116, Korea Cell Line Bank, 10247) was used at 5 × 10 per well of a 96-well plate. 3 Cells were dispensed at 100 μL. The dispensed colon cancer cell line (HCT-116) was cultured in RPMI medium (Gibco) containing 10% FBS (Gibco), antibiotics (Gibco), and glutamax (Gibco) at 37°C and 5% CO2 in a cell incubator.

[0097]

[0098] 2-2. Combined treatment with BTK degraders and Bcl-6 degraders

[0099] In Example 2-1, the colon cancer cell line cultured was treated with a BTK inhibitor (MT-802; BTK decomposer), which is a type of PROTAC-based BTK target drug, alone, a Bcl-6 inhibitor (BI-3802; Bcl-6 decomposer), which is a type of PROTAC-based Bcl-6 target drug, alone, or a combination of the BTK decomposer MT-802 and the Bcl-6 decomposer BI-3802, and the results were confirmed.

[0100] Specifically, a negative control group was set by treating cultured colon cancer cell lines with DMSO, a positive control group was set by treating them alone with 5 μM or 10 μM of the BTK degrader MT-802 or the Bcl-6 degrader BI-3802, and an experimental group was set by treating them together with 5 μM of the BTK degrader MT-802 and the Bcl-6 degrader BI-3802.

[0101] After treating each colon cancer cell line according to the conditions, they were cultured in a CO2 incubator for 72 hours. Then, to confirm the viability of each group of colon cancer cell lines using the CCK-8 assay, 10 μL of CCK-8 (Cell Counting Kit-8, BIOMAX) reagent was stimulated per well, and after 2 hours, the absorbance was measured at 450 nm. The results are shown in Table 2 and Figure 2.

[0102] Treatment group absorbance (OD) Control group 1.088 MT-802; BTK degrader alone treatment group (5 μM) 0.644 MT-802; BTK degrader alone treatment group (10 μM) 0.592 BI-3802; Bcl-6 degrader alone treatment group (5 μM) 0.729 BI-3802; Bcl-6 degrader alone treatment group (10 μM) 0.545 MT-802; BTK degrader (5 μM) + BI-3802; Bcl-6 degrader (5 μM) combined treatment group 0.397

[0103]

[0104] As a result of the analysis, in the colon cancer cell line (HCT-116), the absorbance of the BTK decomposition agent MT-802 alone treatment group and the Bcl-6 decomposition agent BI-3802 alone treatment group were 0.592 and 0.545, respectively, at 10 μM, whereas the absorbance of the combined treatment group of the BTK decomposition agent MT-802 (5 μM) and the Bcl-6 decomposition agent BI-3802 (5 μM) was 0.397, confirming a statistically significant decrease in value.

[0105] That is, it was confirmed that the combined treatment group of MT-802, a BTK inhibitor, and BI-3802, a Bcl-6 inhibitor, had a superior cell growth inhibition effect compared to the single treatment group in the colon cancer cell line, and the absorbance of the BTK decomposition agent MT-802 10 μM single treatment group and the Bcl-6 decomposition agent BI-3802 10 μM single treatment group was 0.397, which is lower than the average value of (0.592 + 0.545) / 2 = 0.5685, confirming the existence of a synergistic effect.

[0106]

[0107] Example 3: Experimental study of combined treatment with BTK degraders and Bcl-6 degraders on T-cell leukemia cell lines.

[0108] 3-1. Culturing of T-cell leukemia cell lines

[0109] Using a T-cell leukemia cell line (Jurkat; Jurkat clone E6-1, Korea Cell Line Bank, 40152), 5 × 10 cells were seeded per well of a 96-well plate. 3 Cells were dispensed at 100 μL. T-cell leukemia cell line (Jurkat) was cultured in RPMI medium (Gibco) containing 10% FBS (Gibco), antibiotics (Gibco), and glutamax (Gibco) at 37°C and 5% CO2 in a cell incubator.

[0110]

[0111] 3-2. Combined treatment with BTK degraders and Bcl-6 degraders

[0112] Through Example 3-1, the T-cell leukemia cell line (Jurkat) cultured was treated with a BTK inhibitor (MT-802; BTK decomposer), which is a type of PROTAC-based BTK target drug, alone, a Bcl-6 inhibitor (BI-3802; Bcl-6 decomposer), which is a type of PROTAC-based Bcl-6 target drug, alone, or a combination of the BTK decomposer MT-802 and the Bcl-6 decomposer BI-3802, and the results were confirmed.

[0113] Specifically, a negative control group was set by treating cultured T-cell leukemia cell line (Jurkat) with DMSO, a positive control group was set by treating alone 5 μM or 10 μM of BTK degrader MT-802 or Bcl-6 degrader BI-3802, and an experimental group was set by treating together 5 μM of BTK degrader MT-802 and Bcl-6 degrader BI-3802.

[0114] After treating each T-cell leukemia cell line (Jurkat) according to each condition, they were cultured in a CO2 incubator for 72 hours. Then, to confirm the viability of the T-cell leukemia cell line of each group using the CCK-8 assay, the CCK-8 (Cell Counting Kit-8, BIOMAX) reagent was stimulated at 10 μL per well, and the absorbance was measured at 450 nm after 2 hours. The results are shown in Table 3 and Figure 3.

[0115] Treatment group absorbance (OD) Control group 0.610 MT-802; BTK degrader alone treatment group (5 μM) 0.245 MT-802; BTK degrader alone treatment group (10 μM) 0.182 BI-3802; Bcl-6 degrader alone treatment group (5 μM) 0.607 BI-3802; Bcl-6 degrader alone treatment group (10 μM) 0.280 MT-802; BTK degrader (5 μM) + BI-3802; Bcl-6 degrader (5 μM) combined treatment group 0.175

[0116]

[0117] As a result of the analysis, the absorbance of the BTK degrader MT-802 alone treatment group and the Bcl-6 degrader BI-3802 alone treatment group in the T cell leukemia cell line (Jurkat) was 0.182 and 0.280 at 10 μM, respectively, whereas the absorbance of the combined treatment group of the BTK degrader MT-802 (5 μM) and the Bcl-6 degrader BI-3802 (5 μM) was 0.175, showing a significant decrease in value.

[0118] That is, the combined treatment group of MT-802, a BTK inhibitor, and BI-3802, a Bcl-6 inhibitor, was confirmed to have a superior cell growth inhibition effect compared to the single treatment group in the T cell leukemia cell line, and the absorbance of the combined treatment group of MT-802 (5 μM), a BTK decomposition agent, and BI-3802 (5 μM), a Bcl-6 decomposition agent, was 0.175 lower than the average value of the absorbance of the single treatment group of MT-802 (10 μM), a BTK decomposition agent, and the single treatment group of BI-3802 (10 μM), a Bcl-6 decomposition agent, (0.182 + 0.280) / 2 = 0.231, confirming the existence of a synergistic effect.

[0119]

[0120] Example 4: Experimental study of combined treatment with BTK degraders and Bcl-6 degraders on lung cancer cell lines.

[0121] 4-1. Culturing lung cancer cell lines

[0122] Lung cancer cell line (A549; A-549, Korea Cell Line Bank, 10185) was seeded at 5 × 10 per well of a 96-well plate. 3 Cells were dispensed at 100 μL. The dispensed lung cancer cell line (A549) was cultured in RPMI medium (Gibco) containing 10% FBS (Gibco), antibiotics (Gibco), and glutamax (Gibco) at 37°C and 5% CO2 in a cell incubator.

[0123]

[0124] 4-2. Combined treatment with BTK degraders and Bcl-6 degraders

[0125] In Example 4-1, a BTK inhibitor (MT-802; BTK decomposer), which is a type of PROTAC-based BTK target drug, was treated alone, a Bcl-6 inhibitor (BI-3802; Bcl-6 decomposer), which is a type of PROTAC-based Bcl-6 target drug, was treated alone, or a combination of the BTK decomposer MT-802 and the Bcl-6 decomposer BI-3802 was treated, and the results were confirmed.

[0126] Specifically, a negative control group was set by treating cultured lung cancer cell lines with DMSO, a positive control group was set by treating them alone with 5 μM or 10 μM of the BTK degrader MT-802 or the Bcl-6 degrader BI-3802, and an experimental group was set by treating them together with 5 μM of the BTK degrader MT-802 and the Bcl-6 degrader BI-3802.

[0127] After treating lung cancer cell lines according to each condition, they were cultured in a CO2 incubator for 72 hours. Then, to confirm the viability of lung cancer cell lines in each group using the CCK-8 assay, 10 μL of CCK-8 (Cell Counting Kit-8, BIOMAX) reagent was stimulated per well, and after 2 hours, the absorbance was measured at 450 nm. The results are shown in Table 4 and Figure 4.

[0128] Treatment group absorbance (OD) Control group 2.391 MT-802; BTK degrader alone treatment group (5 μM) 2.260 MT-802; BTK degrader alone treatment group (10 μM) 1.712 BI-3802; Bcl-6 degrader alone treatment group (5 μM) 2.268 BI-3802; Bcl-6 degrader alone treatment group (10 μM) 1.626 MT-802; BTK degrader (5 μM) + BI-3802; Bcl-6 degrader (5 μM) combined treatment group 1.402

[0129]

[0130] As a result of the analysis, the absorbance of the BTK decomposition agent MT-802 alone treatment group and the Bcl-6 decomposition agent BI-3802 alone treatment group in the lung cancer cell line (A549) was 1.712 and 1.626 at 10 μM, respectively, whereas the absorbance of the combined treatment group of the BTK decomposition agent MT-802 (5 μM) and the Bcl-6 decomposition agent BI-3802 (5 μM) was 1.402, showing a significant decrease.

[0131] In addition, the absorbance of the BTK decomposition agent MT-802 single treatment group and the Bcl-6 decomposition agent BI-3802 single treatment group was 2.260 and 2.268, respectively, at 5 μM, whereas the absorbance of the combined treatment group of the BTK decomposition agent MT-802 (5 μM) and the Bcl-6 decomposition agent BI-3802 (5 μM) was significantly reduced to 1.402.

[0132] That is, it was confirmed that the combined treatment group of MT-802, a BTK inhibitor, and BI-3802, a Bcl-6 inhibitor, had a superior cell growth inhibition effect compared to the single treatment group in lung cancer cell lines, and the average value of the absorbance of the BTK decomposition agent MT-802 10 μM single treatment group and the Bcl-6 decomposition agent BI-3802 10 μM single treatment group was (1.712 + 1.626) / 2 = 1.669, which was lower than the absorbance of the combined treatment group of MT-802 (5 μM), a BTK decomposition agent, and BI-3802 (5 μM), a Bcl-6 decomposition agent, at 1.402, confirming a synergistic effect.

[0133] The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a BTK degrader and a Bcl-6 degrader. The pharmaceutical composition of the present invention not only has a preventive or therapeutic effect on cancer by selectively degrading target proteins through the BTK degrader and Bcl-6 degrader of the present invention based on the proteolysis-targeting chimera (PROTAC) technology, but can also create a therapeutic effect on cancer that is resistant to conventional drugs.

Claims

1. A pharmaceutical composition for preventing or treating cancer, comprising a BTK decomposer and a Bcl-6 decomposer as active ingredients.

2. A pharmaceutical composition according to claim 1, characterized in that the BTK decomposer and Bcl-6 decomposer are based on PROTAC (Proteolysis targeting chimera).

3. A pharmaceutical composition according to claim 1, wherein the BTK decomposer is MT-802.

4. A pharmaceutical composition according to claim 1, wherein the Bcl-6 decomposer is BI-3802.

5. A pharmaceutical composition according to claim 1, wherein the molar ratio of the BTK decomposer and the Bcl-6 decomposer is 1:3 to 3:

1.

6. A pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises a BTK decomposer at a concentration of 1 to 20 μM and a Bcl-6 decomposer at a concentration of 1 to 20 μM.

7. A pharmaceutical composition according to claim 1, wherein the cancer is at least one selected from the group consisting of leukemia, lymphoma, multiple myeloma, colorectal cancer, and lung cancer.

Citation Information

Patent Citations

  • Apparatus for eliminating residual heat of nuclear reactor, assembly including the same and method of eliminating residual heat of nuclear reactor

    KR102807641B1

  • Inhibitors of bruton's tyrosine kinase and methods of their use

    US20230012167A1

  • Targeted protein degradation system and use thereof

    WO2022161502A1